Several pharmacological properties are attributed to ergot alkaloids as a result of their antibacterial, antiproliferative, and antioxidant effects. Although known for their biomedical applications (e.g., for the treatment of glaucoma), most ergot alkaloids exhibit high toxicological risk and may even be lethal to humans and animals. Their pharmacological profile results from the structural similarity between lysergic acid‐derived compounds and noradrenalin, dopamine, and serotonin neurotransmitters. To reduce their toxicological risk, while increasing their bioavailability, improved delivery systems were proposed. This review discusses the safety aspects of using ergot alkaloids in ocular pharmacology and proposes the development of lipid and polymeric nanoparticles for the topical administration of these drugs to enhance their therapeutic efficacy for the treatment of glaucoma.
Natural ergot alkaloids in ocular pharmacotherapy: known molecules for novel delivery systems / Baldim, Iara; Pereira Oliveira, Wanderley; Kadian, Varsha; Rao, Rekha; Yadav, Nitesh; Mahant, Sheefali; Lucarini, Massimo; Durazzo, Alessandra; Da Ana, Raquel; Capasso, Raffaele; Souto, Selma B.; Santini, Antonello; Barbosa Souto, Eliana. - In: BIOMOLECULES. - ISSN 2218-273X. - 10:980(2020). [10.3390/biom10070980]
Natural ergot alkaloids in ocular pharmacotherapy: known molecules for novel delivery systems.
Raffaele Capasso;Antonello Santini
;
2020
Abstract
Several pharmacological properties are attributed to ergot alkaloids as a result of their antibacterial, antiproliferative, and antioxidant effects. Although known for their biomedical applications (e.g., for the treatment of glaucoma), most ergot alkaloids exhibit high toxicological risk and may even be lethal to humans and animals. Their pharmacological profile results from the structural similarity between lysergic acid‐derived compounds and noradrenalin, dopamine, and serotonin neurotransmitters. To reduce their toxicological risk, while increasing their bioavailability, improved delivery systems were proposed. This review discusses the safety aspects of using ergot alkaloids in ocular pharmacology and proposes the development of lipid and polymeric nanoparticles for the topical administration of these drugs to enhance their therapeutic efficacy for the treatment of glaucoma.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
